Form D · Biotechnology

INTERCEPT PHARMACEUTICALS INC

New York, NY · CIK 0001270073

Offering snapshot reported Sep 4, 2012 · SEC filing

Reported sold: $30M
Investors reported: 2
Minimum accepted: $0
First sale: Aug 9, 2012

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$15,000,000 → $30,000,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 4, 2012	Amendment	$30,000,000	$15,000,000vs Aug 24, 2012	2	SEC filing
Aug 24, 2012	Initial	$15,000,000	No comparison	2	SEC filing
May 23, 2006	Paper	Not reported	No comparison	Not reported

Offering details

Securities: Equity
Exemptions: 06
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-183201

Source: Form D, filed Sep 4, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Luciano Adorini	Executive
Barbara Duncan	Executive
Paolo Fundaro	Director
Mark E. Pruzanski	Director, Executive
David Shapiro	Executive
Jonathan T. Silverstein	Director
Lorenzo Tallarigo	Director
Klaus Veitinger	Director
Klaus Veltinger	Director
Nicole Williams	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

18 Desbrosses Street
New York, NY, 10013